| abstract |
The invention provides an immune adjuvant, an inactivated vaccine and a preparation method thereof, and belongs to the field of veterinary biopharmaceuticals. The immunoadjuvant contains 1.0‐10 mg/mL cationic guar, 1.0‐10 mg/mL poloxamer, 1.0‐10 mg/mL mannan peptide, 1.0‐10 mg/mL saponin QS‐21, 20‐ 100 mg/mL glycerol, 5-50 mg/mL sucrose. The immunoadjuvant uses poloxamer and cationic guar as a sustained release agent, which is beneficial to the adhesion of the vaccine to the respiratory and digestive tract of poultry, and has a sustained release effect and an increase in antigen storage time; mannan peptide and saponin QS-21 can significantly increase mucosal immunity as an immunopotentiator; glycerol and sucrose can protect the structural stability of the antigen under body temperature conditions, thereby increasing the duration of antigen action. The vaccine uses spray immunization and oral immunization to achieve automated immunization of large-scale farms, significantly reducing labor costs and reducing the risk of human-induced immune failure. |